Results 71 to 80 of about 4,608 (197)

Pathology of a Canine Model of Localized Prostate Carcinoma

The Prostate, Volume 86, Issue 1, Page 65-83, January 2026.
ABSTRACT Background Dogs spontaneously develop prostate carcinoma (PC) and share prostate gland anatomy, physiology, and size to men. Over the last 15 years, we have developed and refined a canine model of focal PC to evaluate therapeutic‐diagnostic (theranostic) interventions.
Nathan K. Hoggard, Felipe M. Berg, Marlon R. Szczepaniak, Xinning Wang, Noriko Kantake, Gopalakrishnan Ramamurthy, Li Gong, Eric T. Hostnik, Krishan Kumar, Arijit Ghosh, Dong Luo, Michael V. Knopp, Jill M. Keller, Evan T. Keller, Agata A. Exner, James P. Basilion, Michael F. Tweedle, Thomas J. Rosol   +17 more
wiley   +1 more source

The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next? [PDF]

, 2022
Philip E. Harris, Konstantin Zhernosekov
openalex   +1 more source

Systematic review and meta‐analysis of the efficacy and safety of [177Lu]Lu‐edotreotide ([177Lu]Lu‐DOTATOC) for the treatment of neuroendocrine tumors

Journal of Neuroendocrinology, Volume 38, Issue 1, January 2026.
Abstract [177Lu]Lu‐edotreotide is a radiopharmaceutical therapy (RPT) targeting somatostatin receptors, which are commonly overexpressed on neuroendocrine tumors (NETs). This systematic literature review and meta‐analysis describes the efficacy and safety of [177Lu]Lu‐edotreotide in patients with NETs.
Richard P. Baum, Julia G. Fricke, Tristan Ruhwedel, Holger Amthauer, Erika Patricia Azorin‐Vega, Dieter Hörsch, Riccardo Laudicella, Vikalp Maheshwari, Martin A. Walter, Berna Degirmenci Polack, Simon F. Spiegl, Guillaume P. Nicolas   +11 more
wiley   +1 more source

Dosimetry methods and clinical applications in peptide receptor radionuclide therapy for neuroendocrine tumours: a literature review

EJNMMI Research, 2018
Background The main challenge for systemic radiation therapy using radiopharmaceuticals (SRT) is to optimise the dose delivered to the tumour, while minimising normal tissue irradiation.
Daphne Merel Valerie Huizing, Berlinda Jantina de Wit-van der Veen, Marcel Verheij, Marcellus Petrus Maria Stokkel   +3 more
doaj   +1 more source

Long-term Nephrotoxicity after PRRT: Myth or Reality

Theranostics
Rationale: The kidneys are commonly considered as the potential dose-limiting organ for peptide receptor radionuclide therapy (PRRT), making the risk of nephrotoxicity a primary concern. This retrospective analysis with prospective documentation and long-term follow-up aims to assess the risk of nephrotoxicity after PRRT in a large cohort of patients ...
Baum, Richard P., Fan, Xin, Jakobsson, Vivianne, Yu, Fei, Schuchardt, Christiane, Chen, Xiaoyuan, Zhang, Jingjing   +6 more
openaire   +2 more sources

Somatostatin analogs in neuroendocrine tumors with Ki‐67 index of ≥10%

Journal of Neuroendocrinology, Volume 38, Issue 1, January 2026.
Abstract Somatostatin analogs (SSAs) are an established first‐line therapy in intestinal and pancreatic neuroendocrine tumors (NETs). Based on Phase III studies, their use is recommended in NET with a Ki‐67 index of up to 10%. The effect of first‐line SSA therapy on differentiated NET with a Ki‐67 index ≥10% is poorly understood.
Johanna Braegelmann, Annie Mathew, Boerge Schmidt, Hamza Kalisch, Wolfgang P. Fendler, Dagmar Führer‐Sakel, Harald Lahner   +6 more
wiley   +1 more source

Long-term results of multimodal peptide receptor radionuclide therapy and fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma

Clinical and Translational Radiation Oncology, 2020
Background: The combination of somatostatin receptor-directed peptide receptor radionuclide therapy (PRRT) in combination with external beam radiotherapy (EBRT) might prove a feasible treatment option in patients with advanced meningioma.
Philipp E. Hartrampf, Heribert Hänscheid, Olivia Kertels, Andreas Schirbel, Michael C. Kreissl, Michael Flentje, Reinhart A. Sweeney, Andreas K. Buck, Bülent Polat, Constantin Lapa   +9 more
doaj   +1 more source

Bone metastases from neuroendocrine neoplasms: Results of an Italian nationwide survey of natural history and management

Journal of Neuroendocrinology, Volume 38, Issue 1, January 2026.
Abstract Bone metastases (BMs) were reported in <15% of cases of neuroendocrine neoplasms (NENs). Their clinical behavior is various and clinical management is still undefined. This study aimed to describe the clinical practical management and survival outcome of neuroendocrine neoplasm patients with BMs.
Nicola Fazio, Patrick Maisonneuve, Anna Maria Frezza, Nicoletta Ranallo, Toni Ibrahim, Anna La Salvia, Maria Pia Brizzi, Chiara De Divitiis, Salvatore Tafuto, Sara Pusceddu, Riccardo Marconcini, Mauro Cives, Cristina Ferrari, Davide Campana, Delia De Lisi, Daniele Santini, Antongiulio Faggiano, Roberta Modica, Sara Massironi, Antonio Bianchi, Francesco Panzuto, Lorenzo Antonuzzo, Elisa Pellegrini, Vito Amoroso, Ivana Puliafito, Elettra Merola, Nicola Silvestris, Chiara Maria Grana, Francesca Spada   +28 more
wiley   +1 more source

Tumor growth rate in pancreatic neuroendocrine tumor patients undergoing PRRT with 177Lu-DOTATATE [PDF]

, 2021
Olof Pettersson, Katarzyna Fröss‐Baron, Joakim Crona, Anders Sundin   +3 more
openalex   +1 more source

Nonmetastatic Pulmonary Carcinoid Presenting With Carcinoid Syndrome Despite Negative 5‐HIAA: A Case Report

Case Reports in Endocrinology, Volume 2026, Issue 1, 2026.
Background Carcinoid syndrome from pulmonary carcinoids without hepatic metastases is rare and diagnostically challenging when biochemical markers are normal. Case Presentation A woman in her mid‐60 s presented with an incidental right adrenal mass during evaluation for dyspnea and elevated D‐dimer.
Aditya Chauhan, Muhammed Kizilgul, Emilian Racila, Kidmealem Zekarias, Kalyani Sen   +4 more
wiley   +1 more source